ArticlebioRxiv : the preprint server for biology2025
Inactivating conditions of therapeutic mycobacteriophages.
Andrew Wiggins, Umar N Chaudhry, Fabiana Bisaro, Addison Lueck, Alan A Schmalstig, Graham F Hatfull, David B Hill, Miriam Braunstein
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Andrew WigginsMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Umar N ChaudhryDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Fabiana BisaroMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Addison LueckMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Alan A SchmalstigDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
David B HillMarsico Lung Institute and Lampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Miriam BraunsteinMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0003-1180-0030 Funding
Vector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Martina Gentzsch · 2004 to 2026
$26.5MINFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5MIn vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infectionR01AI176834 · NIAID · COLORADO STATE UNIVERSITY · PI Miriam S. Braunstein, Gauri G Rao · 2024 to 2026
$2.4MDynamics of viral host range evolutionR01GM116884 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HATFULL, GRAHAM F. · 2015 to 2019
$2.0MEffect of Microenvironment on the Activity of Mycobacteriophages for Treating Mycobacterium abscessusR21AI163677 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BRAUNSTEIN, MIRIAM S. · 2021 to 2022
$428kNIAID NIH HHS R01 AI176834NIAID NIH HHS R21 AI163677NIAID NIH HHS T32 AI007151NIDDK NIH HHS P30 DK065988NIGMS NIH HHS R01 GM116884
6 · The paper itselfAbstract
There is a need for new therapies to treat drug resistant nontuberculous mycobacteria (NTM) disease. Bacteriophages (phages), which are viruses that infect and kill bacteria, are actively being explored as an alternative approach for treating mycobacterial diseases. Several compassionate-use cases of phage therapy for drug resistant NTM infections exhibit favorable outcomes. To further the development of phage therapy it is important to recognize and avoid conditions that negatively impact phage activity during phage production, storage, formulation, or treatment. Conversely, there is a need to inactivate free phages in certain preclinical phage therapy experiments. In this study, we investigated three mycobacteriophages BPsΔ
Indexed as
BacteriophagemycobacteriophageNontuberculous Mycobacteria
Identifiers
PMID41256447
PMCPMC12621657
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390